Aldo Magnini has been appointed managing director of Clariant's
pharmaceuticals ingredients manufacturing business in Italy, based
around the company's two manufacturing plants in Origgio and Isso.
Dutch firm Crucell has expanded its licensing agreement with US
drug major Merck & Co relating to PER.C6, the former's
proprietary cell technology platform used for the production of
biopharmaceutical products.
Japanese drugmaker Eisai is planning to double the production
capacity for its two top-selling drugs - Pariet and Aricept - by
2004, with an investment of ¥9 billion (€65m).
The European Union's Employment, Social Policy, Health and Consumer
Affairs Council agreed on 2 June not to press ahead with proposals
to implement a mandatory centralised marketing authorisation scheme
for all medicines.
Germany-based drugmaker Merck KGaA has launched a major
restructuring of its R&D activities after shelving two of its
early-stage diabetes product candidates, EML 16336 and IDD 676.
Ireland's QUMAS has said it will launch its latest regulatory
compliance product, QUMAS Visa, at the 39th Annual Meeting of the
Drug Information Association in San Antonio, Texas, 15-19 June.
One of Pfizer Global R&D's major research facilities, based in
Nerviano, Italy, has signed an expanded agreement with PerkinElmer
in which the latter will provide repair, maintenance and validation
services for sophisticated...
A science and technology advisory group has called on the Irish
government to ensure that the country remains competitive in the
pharmaceutical and chemical industries by developing R&D
operations and, in particular, fostering...
The European Commission has published a draft monograph in the
European Pharmacopoeia for BASF's recently-introduced
sustained-release coating polymer Kollicoat SR 30 D and a modified
monograph for Kollicoat MAE 30 DP.
UK firm Cobra Bio-Manufacturing has announced its intention to
undertake a placing and open offer to raise £4.65 million (€6.45m)
to fund the purchase of an additional manufacturing plant in
Cowley, Oxford.
The European Federation of Pharmaceutical Industries and
Associations has called for the European Commission to set up a
more favourable legal framework to help the region's pharmaceutical
industry compete with its peers in the...
UK company SkyePharma is expecting to achieve turnover of £100
million (€139m) in 2003, which would represent a rise of around 40
per cent over last year. However, the company has warned that the
lion's share of this total would...
Reports in Ireland have suggested that Germany's Schwarz Pharma is
planning to scale back its operations in Shannon and cut its
workforce. The company is allegedly planning to reduce its Irish
workforce by 70 to around 180 staff.
US biopharmaceutical firm Acceptys has licensed an immortal
humanised cell line from Columbia University, which will allow it
to discover and produce fully human monoclonal antibodies and other
human proteins for use as therapeutic...
Speciality chemical company Rohm and Haas has created a new
business unit, Advanced Biosciences, that specialises in the
production and purification of biopharmaceuticals. The new unit is
well placed to address the shortfall in production...
The European Commission has given the go-ahead for Germany to grant
a proposed €78 million in aid to help Merck KGaA build a new
biopharmaceuticals plant for the production of oncology products in
Jena, Thuringen.
Switzerland's Solvias AG, a specialist in scientific and technical
services and products based on synthesis and analysis, has reported
a healthy 20 per cent hike in 2002 sales to SF43.6 million
(€28.6m). The increase was driven...
US pharmaceutical major Eli Lilly has earmarked a hefty £220
million (€304 million) investment over the next four years in its
UK facilities, representing the largest investment by the firm in
any European country.
US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis...
Belgian pharmaceutical and chemicals firm Solvay expects to launch
a new version of its Influvac brand flu vaccine, based on a novel
cell-based production process, in 2005. The speed of the new
process means that a vaccine can be...
Sweden's Amarin Development has been commissioned by GEA
Farmaceutisk Fabrik, a Danish subsidiary of German pharmaceutical
company HEXAL, to develop a formulation of one of its candidate
compounds.
Drug delivery company Atrix Laboratories confirmed this week that
the German regulatory authority, Bundesinstitut fur Arzneimittel
und Medizinprodukte (BfArM), had recently completed a successful
inspection of Atrix's manufacturing...
BASF AG's Fine Chemicals division is expanding production of
pharmaceutical active ingredients with the construction of a new
plant at its site in Minden, Germany. A spokesman for the company
told In-pharmatechnologist.com that...
New bulk drug manufacturing facilities, worth a total of around
€123 million (£90 million), were officially opened this week at
AstraZeneca's Avlon Works near Bristol in the UK.
As this edition of In-pharmatechnologist.com goes online, the US
Food and Drug Administration is convening the inaugural meeting of
its Advisory Committee for Pharmaceutical Science's Manufacturing
Subcommittee.
An international conference serving global centres of excellence
for biotechnology, so-called 'bio-technopoles,' life science parks
and 'bio-incubators' will take place ahead of the 7th European
Biotech Crossroads...
BASF Plant Science, the plant biotechnology subsidiary of chemical
giant BASF, has entered into an agreement with Cellectis,
specialists in genome engineering and a recent spin-off from the
Institut Pasteur, that will provide BASF...
The Smart Active Labels Consortium is to present its first seminar,
titled "Smart Active Labels for Temperature Tracking: Shaping
the Future of Food/Pharmaceutical Distribution," on June 10 -
11 in Chicago, US.
The proposed sale of Roche vitamins to Dutch firm DSM is to go
through second phase merger investigations by the European
Commission due to competition concerns in the feed enzymes market.
Attendance at SupplySide East earlier this month was slightly up on
last year, according to organisers, and although there were few
product launches, the conference provided all the drama.
Thermo Electron Corp has presented a new range of instruments at
the ACHEMA meeting in Frankfurt, Germany, including what it says is
the world's first mass spectrometer to combine Ion Trap and Fourier
Transform Ion Cyclotron...
Cambridge Antibody Technology of the UK has signed up for a
non-exclusive licence to a technology, developed by Canada's
Chromos Molecular Systems, for the commercial manufacture of
biologics.
Celsis International of the UK, a specialist in diagnostic systems
to detect and measure microbial contamination for the
pharmaceutical, personal care and food industries, has signed up
Boots Manufacturing (BM) as a new customer.
Netherlands-based drugs, coatings and chemical maker Akzo Nobel has
announced a €500 million divestment program and suggested that it
is unlikely to remain a player in all three of these sectors in the
long term.
UK-based vaccine maker PowderJect is now said to be in the latter
stages of takeover negotiations, with the interested party widely
tipped to be the USA's Chiron, rumoured to be proferring a bid
valuing the company at around...
Dutch life sciences company DSM has broken ground on a new site in
Montreal, Canada, set to become a large-scale biopharmaceuticals
plant. Phase one - at a cost of €100m - due for completion by 2005.
In the US this week, supplier of botanical extracts for the
pharmaceutical industry Pharmachem Laboratories announced that it
has acquired 'the largest botanical extraction facility in North
America, producing extracts for the...
Three major players will try to recover costs from Pan
Pharmaceuticals after Australia's largest ever medical products
recall, reports IndustrySearch.com.
An EU funded project is building the critical mass of knowledge
required to ensure that Europe meets the Lisbon objective of
becoming the world's most competitive knowledge-based economy by
2010, reports Cordis.
The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...
Strasbourg, France-based Aventis has signed a research, option and
license agreement with Vivalis of the USA for the manufacture of
vaccine candidates using avian stem cell technology.
The European Commission has proposed new regulations allowing
Member States to grant aid for research and development (R&D)
to small and medium sized enterprises (SMEs), without having to
first apply for clearance from the Commission,...
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US manufacturer of vitamins, minerals, herbs and supplements
D&E Pharmaceuticals, has launched a contract manufacturing
services initiative, principally aimed at small to medium sized
nutraceutical suppliers.
US zuChem, a development-stage company that focuses on
commercialising manufacturing processes for glycochemicals, has
raised a considerable chunk of capital. Funds earmarked for
development of new sugar-based pharmaceutical intermediates.
BioInnovators, a USA-based consultancy serving the pharmaceutical
and biotech industries, has developed a new set of tools designed
to help pharmaceutical and dietary supplement companies understand
and improve cost and time efficiencies...
A new collaboration sees Hitachi Software Engineering (HSW)
acquiring the rights from German MWG-Biotech to produce DNA
microarrays for sale solely in Japan.
In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.
ChemAxon, Hungarian company that provides software solutions for
biotechnology, has released its latest version of the Java database
engine enabling chemical communication across networks.
